{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T09:50:38Z","timestamp":1790416238709,"version":"4.1.0"},"reference-count":162,"publisher":"Bentham Science Publishers Ltd.","issue":"35","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"funder":[{"DOI":"10.13039\/100008982","name":"ECRA, Qatar National Research Fund","doi-asserted-by":"publisher","award":["ECRA02-007-3-006"],"award-info":[{"award-number":["ECRA02-007-3-006"]}],"id":[{"id":"10.13039\/100008982","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Metformin has been used as an oral anti-hyperglycaemic drug since the late\n1950s; however, following the release in 1998 of the findings of the 20-year United Kingdom\nProspective Diabetes Study (UKPDS), metformin use rapidly increased and today is\nthe first-choice anti-hyperglycaemic drug for patients with type 2 diabetes (T2D). Metformin\nis in daily use by an estimated 150 million people worldwide. Historically, the benefits\nof metformin as an anti-diabetic and cardiovascular-protective drug have been linked\nto effects in the liver, where it acts to inhibit gluconeogenesis and lipogenesis, as well as\nreduce insulin resistance and enhance peripheral glucose utilization. However, direct protective\neffects on the endothelium and effects in the gut prior to metformin absorption are\nnow recognized as important. In the gut, metformin modulates the glucagon-like peptide-\n1 (GLP-1) - gut-brain axis and impacts the intestinal microbiota. As the apparent\nnumber of putative tissue and cellular targets for metformin has increased, so has the interest\nin re-purposing metformin to treat other diseases that include polycystic ovary syndrome\n(PCOS), cancer, neurodegenerative diseases, and COVID-19. Metformin is also\nbeing investigated as an anti-ageing drug. Of particular interest is whether metformin provides\nthe same level of vascular protection in individuals other than those with T2D, including\nobese individuals with metabolic syndrome, or in the setting of vascular thromboinflammation\ncaused by SARS-CoV-2. In this review, we critically evaluate the literature\nto highlight clinical settings in which metformin might be therapeutically repurposed\nfor the prevention and treatment of vascular disease.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929867329666220729154615","type":"journal-article","created":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T04:48:50Z","timestamp":1659329330000},"page":"3955-3978","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Repurposing Metformin for Vascular Disease"],"prefix":"10.2174","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5307-0537","authenticated-orcid":true,"given":"Chris R.","family":"Triggle","sequence":"first","affiliation":[{"name":"Department of Pharmacology &amp; Medical Education, Weill Cornell Medicine in Qatar, PO Box 24144, Education\nCity, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7028-3614","authenticated-orcid":true,"given":"Isra","family":"Marei","sequence":"additional","affiliation":[{"name":"Department of Pharmacology &amp; Medical Education, Weill Cornell Medicine in Qatar, PO Box 24144, Education\nCity, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5015-4089","authenticated-orcid":true,"given":"Kevin","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Biomedical Physiology &amp; Kinesiology, Simon Fraser University,\nBurnaby, British Columbia, Canada, V5A 1S6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2164-1870","authenticated-orcid":true,"given":"Hong","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Pharmacology &amp; Medical Education, Weill Cornell Medicine in Qatar, PO Box 24144, Education\nCity, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3751-6468","authenticated-orcid":true,"given":"Todd J.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Department of Cardiac Sciences and Libin Cardiovascular\nInstitute, Cumming School of Medicine, University of Calgary, Calgary, Canada, T2N 4N1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4070-8786","authenticated-orcid":true,"given":"Morley D.","family":"Hollenberg","sequence":"additional","affiliation":[{"name":"Department of\nPhysiology &amp; Pharmacology, and Department of Medicine, Cumming School of Medicine, University of Calgary,\nCanada, T2N 4N1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4455-2072","authenticated-orcid":true,"given":"Michael A.","family":"Hill","sequence":"additional","affiliation":[{"name":"Dalton Cardiovascular Research Center &amp; Department of Medical Pharmacology\n&amp; Physiology, School of Medicine, University of Missouri, Columbia 65211, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","first-page":"1295","volume":"36","author":"Sterne J.","year":"1957","unstructured":"Sterne J.; Du nouveau dans les antidiabetiques. La NN dimethylamine guanyl guanide (NNDG). Maroc Med 1957,36,1295-1296","journal-title":"Maroc Med"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"172782","DOI":"10.1016\/j.ejphar.2019.172782","volume":"865","author":"Glossmann H.H.","year":"2019","unstructured":"Glossmann H.H.; Lutz O.M.D.; Pharmacology of metformin - An update. Eur J Pharmacol 2019,865,172782","journal-title":"Eur J Pharmacol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1172\/JCI13505","volume":"108","author":"Zhou G.","year":"2001","unstructured":"Zhou G.; Myers R.; Li Y.; Chen Y.; Shen X.; Fenyk-Melody J.; Wu M.; Ventre J.; Doebber T.; Fujii N.; Musi N.; Hirshman M.F.; Goodyear L.J.; Moller D.E.; Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001,108(8),1167-1174","journal-title":"J Clin Invest"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"e0211568","DOI":"10.1371\/journal.pone.0211568","volume":"14","author":"Muise E.S.","year":"2019","unstructured":"Muise E.S.; Guan H-P.; Liu J.; Nawrocki A.R.; Yang X.; Wang C.; Rodr\u00edguez C.G.; Zhou D.; Gorski J.N.; Kurtz M.M.; Feng D.; Leavitt K.J.; Wei L.; Wilkening R.R.; Apgar J.M.; Xu S.; Lu K.; Feng W.; Li Y.; He H.; Previs S.F.; Shen X.; van Heek M.; Souza S.C.; Rosenbach M.J.; Biftu T.; Erion M.D.; Kelley D.E.; Kemp D.M.; Myers R.W.; Sebhat I.K.; Pharmacological AMPK activation induces transcriptional responses congruent to exercise in skeletal and cardiac muscle, adipose tissues and liver. PLoS One 2019,14(2),e0211568","journal-title":"PLoS One"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","volume":"352","year":"1998","unstructured":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet UK Prospective Diabetes Study (UKPDS) Group1998,352(9131),837-853","journal-title":"Lancet"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","volume":"352","year":"1998","unstructured":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet UK Prospective Diabetes Study (UKPDS) Group1998,352(9131),854-865","journal-title":"Lancet"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","volume":"321","author":"Stratton I.M.","year":"2000","unstructured":"Stratton I.M.; Adler A.I.; Neil H.A.; Matthews D.R.; Manley S.E.; Cull C.A.; Hadden D.; Turner R.C.; Holman R.R.; Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 2000,321(7258),405-412","journal-title":"BMJ"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","volume":"359","author":"Holman R.R.","year":"2008","unstructured":"Holman R.R.; Paul S.K.; Bethel M.A.; Matthews D.R.; Neil H.A.; 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008,359(15),1577-1589","journal-title":"N Engl J Med"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/j.1464-5491.2005.01448.x","volume":"22","author":"Johnson J.A.","year":"2005","unstructured":"Johnson J.A.; Simpson S.H.; Toth E.L.; Majumdar S.R.; Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with type 2 diabetes. Diabet Med 2005,22(4),497-502","journal-title":"Diabet Med"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ijcard.2019.03.021","volume":"291","author":"Jong C.B.","year":"2019","unstructured":"Jong C.B.; Chen K.Y.; Hsieh M.Y.; Su F.Y.; Wu C.C.; Voon W.C.; Hsieh I.C.; Shyu K.G.; Chong J.T.; Lin W.S.; Hsu C.N.; Ueng K.C.; Lai C.L.; Metformin was associated with lower all-cause mortality in type 2 diabetes with acute coronary syndrome: A Nationwide registry with propensity score-matched analysis. Int J Cardiol 2019,291,152-157","journal-title":"Int J Cardiol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1161\/CIRCULATIONAHA.119.040144","volume":"140","author":"Bergmark B.A.","year":"2019","unstructured":"Bergmark B.A.; Bhatt D.L.; McGuire D.K.; Cahn A.; Mosenzon O.; Steg P.G.; Im K.; Kanevsky E.; Gurmu Y.; Raz I.; Braunwald E.; Scirica B.M.; Metformin use and clinical outcomes among patients with diabetes mellitus with or without heart failure or kidney dysfunction: Observations from the SAVOR-TIMI 53 Trial. Circulation 2019,140(12),1004-1014","journal-title":"Circulation"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa012512","volume":"346","author":"Knowler W.C.","year":"2002","unstructured":"Knowler W.C.; Barrett-Connor E.; Fowler S.E.; Hamman R.F.; Lachin J.M.; Walker E.A.; Nathan D.M.; Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002,346(6),393-403","journal-title":"N Engl J Med"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"731","DOI":"10.2337\/dc11-1299","volume":"35","year":"2012","unstructured":"Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care Diabetes Prevention Program Research Group2012,35(4),731-737","journal-title":"Diabetes Care"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12933-019-0900-7","volume":"18","author":"Han Y.","year":"2019","unstructured":"Han Y.; Xie H.; Liu Y.; Gao P.; Yang X.; Shen Z.; Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: A systematic review and an updated meta-analysis. Cardiovasc Diabetol 2019,18(1),96","journal-title":"Cardiovasc Diabetol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1007\/s00125-017-4337-9","volume":"60","author":"Griffin S.J.","year":"2017","unstructured":"Griffin S.J.; Leaver J.K.; Irving G.J.; Impact of metformin on cardiovascular disease: A meta-analysis of randomised trials among people with type 2 diabetes. Diabetologia 2017,60(9),1620-1629","journal-title":"Diabetologia"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"e1001204","DOI":"10.1371\/journal.pmed.1001204","volume":"9","author":"Boussageon R.","year":"2012","unstructured":"Boussageon R.; Supper I.; Bejan-Angoulvant T.; Kellou N.; Cucherat M.; Boissel J-P.; Kassai B.; Moreau A.; Gueyffier F.; Cornu C.; Reappraisal of metformin efficacy in the treatment of type 2 diabetes: A meta-analysis of randomised controlled trials. PLoS Med 2012,9(4),e1001204","journal-title":"PLoS Med"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"h6748","DOI":"10.1136\/bmj.h6748","volume":"352","author":"Boussageon R.","year":"2016","unstructured":"Boussageon R.; Gueyffier F.; Cornu C.; Metformin as firstline treatment for type 2 diabetes: Are we sure? BMJ 2016,352,h6748","journal-title":"BMJ"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/288373a0","volume":"288","author":"Furchgott R.F.","year":"1980","unstructured":"Furchgott R.F.; Zawadzki J.V.; The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980,288(5789),373-376","journal-title":"Nature"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1139\/cjpp-2019-0677","volume":"98","author":"Triggle C.R.","year":"2020","unstructured":"Triggle C.R.; Ding H.; Marei I.; Anderson T.J.; Hollenberg M.D.; Why the endothelium? The endothelium as a target to reduce diabetes-associated vascular disease. Can J Physiol Pharmacol 2020,98(7),415-430","journal-title":"Can J Physiol Pharmacol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1161\/hc0502.104540","volume":"105","author":"Verma S.","year":"2002","unstructured":"Verma S.; Anderson T.J.; Fundamentals of endothelial function for the clinical cardiologist. Circulation 2002,105(5),546-549","journal-title":"Circulation"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1161\/01.CIR.0000028581.07992.56","volume":"106","author":"Vita J.A.","year":"2002","unstructured":"Vita J.A.; Keaney J.F.; Endothelial function: A barometer for cardiovascular risk? Circulation 2002,106(6),640-642","journal-title":"Circulation"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1016\/0735-1097(95)00327-4","volume":"26","author":"Anderson T.J.","year":"1995","unstructured":"Anderson T.J.; Uehata A.; Gerhard M.D.; Meredith I.T.; Knab S.; Delagrange D.; Lieberman E.H.; Ganz P.; Creager M.A.; Yeung A.C.; Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995,26(5),1235-1241","journal-title":"J Am Coll Cardiol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"699","DOI":"10.3390\/biomedicines9060699","volume":"9","author":"Little P.J.","year":"2021","unstructured":"Little P.J.; Askew C.D.; Xu S.; Kamato D.; Endothelial dysfunction and cardiovascular disease: History and analysis of the clinical utility of the relationship. Biomedicines 2021,9(6),699","journal-title":"Biomedicines"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.pharmthera.2018.07.007","volume":"192","author":"Nafisa A.","year":"2018","unstructured":"Nafisa A.; Gray S.G.; Cao Y.; Wang T.; Xu S.; Wattoo F.H.; Barras M.; Cohen N.; Kamato D.; Little P.J.; Endothelial function and dysfunction: Impact of metformin. Pharmacol Ther 2018,192,150-162","journal-title":"Pharmacol Ther"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coph.2018.11.002","volume":"45","author":"Ding H.","year":"2019","unstructured":"Ding H.; Ye K.; Triggle C.R.; Impact of currently used anti-diabetic drugs on myoendothelial communication. Curr Opin Pharmacol 2019,45,1-7","journal-title":"Curr Opin Pharmacol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"9376","DOI":"10.7150\/thno.64706","volume":"11","author":"Ding Y.","year":"2021","unstructured":"Ding Y.; Zhou Y.; Ling P.; Feng X.; Luo S.; Zheng X.; Little P.J.; Xu S.; Weng J.; Metformin in cardiovascular diabetology: A focused review of its impact on endothelial function. Theranostics 2021,11(19),9376-9396","journal-title":"Theranostics"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/biomedicines9010003","volume":"9","author":"Salvatore T.","year":"2020","unstructured":"Salvatore T.; Pafundi P.C.; Galiero R.; Rinaldi L.; Caturano A.; Vetrano E.; Aprea C.; Albanese G.; Di Martino A.; Ricozzi C.; Imbriani S.; Sasso F.C.; Can metformin exert as an active drug on endothelial dysfunction in diabetic subjects? Biomedicines 2020,9(1),3","journal-title":"Biomedicines"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/S0735-1097(01)01129-9","volume":"37","author":"Mather K.J.","year":"2001","unstructured":"Mather K.J.; Verma S.; Anderson T.J.; Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol 2001,37(5),1344-1350","journal-title":"J Am Coll Cardiol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/j.1365-2796.2005.01531.x","volume":"258","author":"Vitale C.","year":"2005","unstructured":"Vitale C.; Mercuro G.; Cornoldi A.; Fini M.; Volterrani M.; Rosano G.M.; Metformin improves endothelial function in patients with metabolic syndrome. J Intern Med 2005,258(3),250-256","journal-title":"J Intern Med"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"c2181","DOI":"10.1136\/bmj.c2181","volume":"340","author":"de Jager J.","year":"2010","unstructured":"de Jager J.; Kooy A.; Lehert P.; Wulffel\u00e9 M.G.; van der Kolk J.; Bets D.; Verburg J.; Donker A.J.; Stehouwer C.D.; Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: Randomised placebo controlled trial. BMJ 2010,340,c2181","journal-title":"BMJ"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/joim.12128","volume":"275","author":"de Jager J.","year":"2014","unstructured":"de Jager J.; Kooy A.; Schalkwijk C.; van der Kolk J.; Lehert P.; Bets D.; Wulffel\u00e9 M.G.; Donker A.J.; Stehouwer C.D.; Long-term effects of metformin on endothelial function in type 2 diabetes: A randomized controlled trial. J Intern Med 2014,275(1),59-70","journal-title":"J Intern Med"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1097\/00005344-198409000-00027","volume":"6","author":"Sirtori C.R.","year":"1984","unstructured":"Sirtori C.R.; Franceschini G.; Gianfranceschi G.; Sirtori M.; Montanari G.; Bosisio E.; Mantero E.; Bondioli A.; Metformin improves peripheral vascular flow in nonhyperlipidemic patients with arterial disease. J Cardiovasc Pharmacol 1984,6(5),914-923","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1002\/cpt1978246683","volume":"24","author":"Sirtori C.R.","year":"1978","unstructured":"Sirtori C.R.; Franceschini G.; Galli-Kienle M.; Cighetti G.; Galli G.; Bondioli A.; Conti F.; Disposition of metformin (N,N-dimethylbiguanide) in man. Clin Pharmacol Ther 1978,24(6),683-693","journal-title":"Clin Pharmacol Ther"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.2337\/dc05-2146","volume":"29","author":"de Aguiar L.G.","year":"2006","unstructured":"de Aguiar L.G.; Bahia L.R.; Villela N.; Laflor C.; Sicuro F.; Wiernsperger N.; Bottino D.; Bouskela E.; Metformin improves endothelial vascular reactivity in first-degree relatives of type 2 diabetic patients with metabolic syndrome and normal glucose tolerance. Diabetes Care 2006,29(5),1083-1089","journal-title":"Diabetes Care"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1111\/dom.12041","volume":"15","author":"Pitocco D.","year":"2013","unstructured":"Pitocco D.; Zaccardi F.; Tarzia P.; Milo M.; Scavone G.; Rizzo P.; Pagliaccia F.; Nerla R.; Di Franco A.; Manto A.; Rocca B.; Lanza G.A.; Crea F.; Ghirlanda G.; Metformin improves endothelial function in type 1 diabetic subjects: A pilot, placebo-controlled randomized study. Diabetes Obes Metab 2013,15(5),427-431","journal-title":"Diabetes Obes Metab"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1161\/CIRCULATIONAHA.117.031735","volume":"137","author":"Rena G.","year":"2018","unstructured":"Rena G.; Lang C.C.; Repurposing metformin for cardiovascular disease. Circulation 2018,137(5),422-424","journal-title":"Circulation"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.jacc.2006.04.088","volume":"48","author":"Jadhav S.","year":"2006","unstructured":"Jadhav S.; Ferrell W.; Greer I.A.; Petrie J.R.; Cobbe S.M.; Sattar N.; Effects of metformin on microvascular function and exercise tolerance in women with angina and normal coronary arteries: A randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 2006,48(5),956-963","journal-title":"J Am Coll Cardiol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/S2213-8587(13)70152-9","volume":"2","author":"Preiss D.","year":"2014","unstructured":"Preiss D.; Lloyd S.M.; Ford I.; McMurray J.J.; Holman R.R.; Welsh P.; Fisher M.; Packard C.J.; Sattar N.; Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): A randomised controlled trial. Lancet Diabetes Endocrinol 2014,2(2),116-124","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12933-019-0860-y","volume":"18","author":"Luo F.","year":"2019","unstructured":"Luo F.; Das A.; Chen J.; Wu P.; Li X.; Fang Z.; Metformin in patients with and without diabetes: A paradigm shift in cardiovascular disease management. Cardiovasc Diabetol 2019,18(1),54","journal-title":"Cardiovasc Diabetol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"756","DOI":"10.3389\/fphar.2017.00756","volume":"8","author":"Huang Y.","year":"2017","unstructured":"Huang Y.; Smith C.A.; Chen G.; Sharma B.; Miner A.S.; Barbee R.W.; Ratz P.H.; The AMP-dependent protein kinase (AMPK) activator A-769662 causes arterial relaxation by reducing cytosolic free calcium independently of an increase in AMPK phosphorylation. Front Pharmacol 2017,8,756","journal-title":"Front Pharmacol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.bbrc.2012.04.052","volume":"421","author":"Sung J.Y.","year":"2012","unstructured":"Sung J.Y.; Choi H.C.; Metformin-induced AMP-activated protein kinase activation regulates phenylephrine-mediated contraction of rat aorta. Biochem Biophys Res Commun 2012,421(3),599-604","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ejphar.2017.01.003","volume":"798","author":"Mori A.","year":"2017","unstructured":"Mori A.; Ishikawa E.; Amano T.; Sakamoto K.; Nakahara T.; Anti-diabetic drug metformin dilates retinal blood vessels through activation of AMP-activated protein kinase in rats. Eur J Pharmacol 2017,798,66-71","journal-title":"Eur J Pharmacol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1161\/CIRCRESAHA.110.223545","volume":"107","author":"Giacco F.","year":"2010","unstructured":"Giacco F.; Brownlee M.; Oxidative stress and diabetic complications. Circ Res 2010,107(9),1058-1070","journal-title":"Circ Res"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1055\/s-2006-955084","volume":"38","author":"Bellin C.","year":"2006","unstructured":"Bellin C.; de Wiza D.H.; Wiernsperger N.F.; R\u00f6sen P.; Generation of reactive oxygen species by endothelial and smooth muscle cells: Influence of hyperglycemia and metformin. Horm Metab Res 2006,38(11),732-739","journal-title":"Horm Metab Res"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.metabol.2005.01.029","volume":"54","author":"Ouslimani N.","year":"2005","unstructured":"Ouslimani N.; Peynet J.; Bonnefont-Rousselot D.; Th\u00e9rond P.; Legrand A.; Beaudeux J-L.; Metformin decreases intracellular production of reactive oxygen species in aortic endothelial cells. Metabolism 2005,54(6),829-834","journal-title":"Metabolism"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"E293","DOI":"10.1152\/ajpendo.00240.2021","volume":"322","author":"Liu J.","year":"2022","unstructured":"Liu J.; Aylor K.W.; Chai W.; Barrett E.J.; Liu Z.; Metformin prevents endothelial oxidative stress and microvascular insulin resistance during obesity development in male rats. Am J Physiol Endocrinol Metab 2022,322(3),E293-E306","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1161\/01.ATV.0000201938.78044.75","volume":"26","author":"Isoda K.","year":"2006","unstructured":"Isoda K.; Young J.L.; Zirlik A.; MacFarlane L.A.; Tsuboi N.; Gerdes N.; Sch\u00f6nbeck U.; Libby P.; Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells. Arterioscler Thromb Vasc Biol 2006,26(3),611-617","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/bph.12496","volume":"171","author":"Arunachalam G.","year":"2014","unstructured":"Arunachalam G.; Samuel S.M.; Marei I.; Ding H.; Triggle C.R.; Metformin modulates hyperglycaemia-induced endothelial senescence and apoptosis through SIRT1. Br J Pharmacol 2014,171(2),523-535","journal-title":"Br J Pharmacol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2337\/db11-0416","volume":"61","author":"Zheng Z.","year":"2012","unstructured":"Zheng Z.; Chen H.; Li J.; Li T.; Zheng B.; Zheng Y.; Jin H.; He Y.; Gu Q.; Xu X.; Sirtuin 1-mediated cellular metabolic memory of high glucose via the LKB1\/AMPK\/ROS pathway and therapeutic effects of metformin. Diabetes 2012,61(1),217-228","journal-title":"Diabetes"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1101\/sqb.2007.72.024","volume":"72","author":"Guarente L.","year":"2007","unstructured":"Guarente L.; Sirtuins in aging and disease. Cold Spring Harb Symp Quant Biol 2007,72,483-488","journal-title":"Cold Spring Harb Symp Quant Biol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.cmet.2007.08.014","volume":"6","author":"Sun C.","year":"2007","unstructured":"Sun C.; Zhang F.; Ge X.; Yan T.; Chen X.; Shi X.; Zhai Q.; SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. Cell Metab 2007,6(4),307-319","journal-title":"Cell Metab"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1161\/01.RES.0000267723.65696.4a","volume":"100","author":"Alcendor R.R.","year":"2007","unstructured":"Alcendor R.R.; Gao S.; Zhai P.; Zablocki D.; Holle E.; Yu X.; Tian B.; Wagner T.; Vatner S.F.; Sadoshima J.; Sirt1 regulates aging and resistance to oxidative stress in the heart. Circ Res 2007,100(10),1512-1521","journal-title":"Circ Res"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.1101\/gad.435107","volume":"21","author":"Potente M.","year":"2007","unstructured":"Potente M.; Ghaeni L.; Baldessari D.; Mostoslavsky R.; Rossig L.; Dequiedt F.; Haendeler J.; Mione M.; Dejana E.; Alt F.W.; Zeiher A.M.; Dimmeler S.; SIRT1 controls endothelial angiogenic functions during vascular growth. Genes Dev 2007,21(20),2644-2658","journal-title":"Genes Dev"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3389\/fendo.2018.00614","volume":"9","author":"Elibol B.","year":"2018","unstructured":"Elibol B.; Kilic U.; High levels of SIRT1 expression as a protective mechanism against disease-related conditions. Front Endocrinol (Lausanne) 2018,9,614","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1161\/CIRCRESAHA.109.215483","volume":"106","author":"Zu Y.","year":"2010","unstructured":"Zu Y.; Liu L.; Lee M.Y.; Xu C.; Liang Y.; Man R.Y.; Vanhoutte P.M.; Wang Y.; SIRT1 promotes proliferation and prevents senescence through targeting LKB1 in primary porcine aortic endothelial cells. Circ Res 2010,106(8),1384-1393","journal-title":"Circ Res"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"14855","DOI":"10.1073\/pnas.0704329104","volume":"104","author":"Mattagajasingh I.","year":"2007","unstructured":"Mattagajasingh I.; Kim C.S.; Naqvi A.; Yamamori T.; Hoffman T.A.; Jung S.B.; DeRicco J.; Kasuno K.; Irani K.; SIRT1 promotes endothelium-dependent vascular relaxation by activating endothelial nitric oxide synthase. Proc Natl Acad Sci USA 2007,104(37),14855-14860","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"718942","DOI":"10.3389\/fendo.2021.718942","volume":"12","author":"Mohammed I.","year":"2021","unstructured":"Mohammed I.; Hollenberg M.D.; Ding H.; Triggle C.R.; A critical review of the evidence that metformin is a putative anti-aging drug that enhances healthspan and extends lifespan. Front Endocrinol (Lausanne) 2021,12,718942","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1124\/molpharm.120.000148","volume":"100","author":"Venu V.K.P.","year":"2021","unstructured":"Venu V.K.P.; Saifeddine M.; Mihara K.; Faiza M.; Gorobets E.; Flewelling A.J.; Derksen D.J.; Hirota S.A.; Marei I.; Al-Majid D.; Motahhary M.; Ding H.; Triggle C.R.; Hollenberg M.D.; MetfZormin prevents hyperglycemia-associated, oxidative stress-induced vascular endothelial dysfunction: Essential role for the orphan nuclear receptor human nuclear receptor 4A1 (Nur77). Mol Pharmacol 2021,100(5),428-455","journal-title":"Mol Pharmacol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/nchembio.1069","volume":"8","author":"Zhan Y.Y.","year":"2012","unstructured":"Zhan Y.Y.; Chen Y.; Zhang Q.; Zhuang J.J.; Tian M.; Chen H.Z.; Zhang L.R.; Zhang H.K.; He J.P.; Wang W.J.; Wu R.; Wang Y.; Shi C.; Yang K.; Li A.Z.; Xin Y.Z.; Li T.Y.; Yang J.Y.; Zheng Z.H.; Yu C.D.; Lin S.C.; Chang C.; Huang P.Q.; Lin T.; Wu Q.; The orphan nuclear receptor Nur77 regulates LKB1 localization and activates AMPK. Nat Chem Biol 2012,8(11),897-904","journal-title":"Nat Chem Biol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1126\/science.275.5302.964","volume":"275","author":"Asahara T.","year":"1997","unstructured":"Asahara T.; Murohara T.; Sullivan A.; Silver M.; van der Zee R.; Li T.; Witzenbichler B.; Schatteman G.; Isner J.M.; Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997,275(5302),964-967","journal-title":"Science"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s00109-004-0580-x","volume":"82","author":"Dimmeler S.","year":"2004","unstructured":"Dimmeler S.; Zeiher A.M.; Vascular repair by circulating endothelial progenitor cells: The missing link in atherosclerosis? J Mol Med (Berl) 2004,82(10),671-677","journal-title":"J Mol Med (Berl)"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1097\/MOH.0000000000000041","volume":"21","author":"Zhang M.","year":"2014","unstructured":"Zhang M.; Malik A.B.; Rehman J.; Endothelial progenitor cells and vascular repair. Curr Opin Hematol 2014,21(3),224-228","journal-title":"Curr Opin Hematol"},{"key":"ref=63","first-page":"13","volume":"2","author":"Berezin A.","year":"2016","unstructured":"Berezin A.; Epigenetically modified endothelial progenitor cells in heart failure. J Clin Epigen 2016,2,13","journal-title":"J Clin Epigen"},{"key":"ref=64","first-page":"27","volume":"6","author":"Berezin A.","year":"2019","unstructured":"Berezin A.; Berezin A.; Endothelial progenitor cell dysfunction in diabetes mellitus. New Target Risk Stratificat Ther 2019,6,27-32","journal-title":"New Target Risk Stratificat Ther"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1002\/sctm.16-0360","volume":"6","author":"Medina R.J.","year":"2017","unstructured":"Medina R.J.; Barber C.L.; Sabatier F.; Dignat-George F.; Melero-Martin J.M.; Khosrotehrani K.; Ohneda O.; Randi A.M.; Chan J.K.Y.; Yamaguchi T.; Van Hinsbergh V.W.M.; Yoder M.C.; Stitt A.W.; Endothelial progenitors: A consensus statement on nomenclature. Stem Cells Transl Med 2017,6(5),1316-1320","journal-title":"Stem Cells Transl Med"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1161\/CIRCULATIONAHA.104.503433","volume":"112","author":"Yoon C.H.","year":"2005","unstructured":"Yoon C.H.; Hur J.; Park K.W.; Kim J.H.; Lee C.S.; Oh I.Y.; Kim T.Y.; Cho H.J.; Kang H.J.; Chae I.H.; Yang H.K.; Oh B.H.; Park Y.B.; Kim H.S.; Synergistic neovascularization by mixed transplantation of early endothelial progenitor cells and late outgrowth endothelial cells: The role of angiogenic cytokines and matrix metalloproteinases. Circulation 2005,112(11),1618-1627","journal-title":"Circulation"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1161\/01.RES.0000189259.69645.25","volume":"97","author":"O\u2019Neill T.J.","year":"2005","unstructured":"O\u2019Neill T.J.; Wamhoff B.R.; Owens G.K.; Skalak T.C.; Mobilization of bone marrow-derived cells enhances the angiogenic response to hypoxia without transdifferentiation into endothelial cells. Circ Res 2005,97(10),1027-1035","journal-title":"Circ Res"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"3546","DOI":"10.1182\/blood-2005-08-3215","volume":"107","author":"Zentilin L.","year":"2006","unstructured":"Zentilin L.; Tafuro S.; Zacchigna S.; Arsic N.; Pattarini L.; Sinigaglia M.; Giacca M.; Bone marrow mononuclear cells are recruited to the sites of VEGF-induced neovascularization but are not incorporated into the newly formed vessels. Blood 2006,107(9),3546-3554","journal-title":"Blood"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/j.jacc.2004.11.067","volume":"45","author":"Fadini G.P.","year":"2005","unstructured":"Fadini G.P.; Miorin M.; Facco M.; Bonamico S.; Baesso I.; Grego F.; Menegolo M.; de Kreutzenberg S.V.; Tiengo A.; Agostini C.; Avogaro A.; Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. J Am Coll Cardiol 2005,45(9),1449-1457","journal-title":"J Am Coll Cardiol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/dmrr.1159","volume":"27","author":"Li M.","year":"2011","unstructured":"Li M.; Ho J.C.; Lai K.W.; Au K.K.; Xu A.; Cheung B.M.; Lam K.S.; Tse H.F.; The decrement in circulating endothelial progenitor cells (EPCs) in type 2 diabetes is independent of the severity of the hypoadiponectemia. Diabetes Metab Res Rev 2011,27(2),185-194","journal-title":"Diabetes Metab Res Rev"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1472-6823-10-5","volume":"10","author":"Churdchomjan W.","year":"2010","unstructured":"Churdchomjan W.; Kheolamai P.; Manochantr S.; Tapanadechopone P.; Tantrawatpan C.; U-Pratya Y.; Issaragrisil S.; Comparison of endothelial progenitor cell function in type 2 diabetes with good and poor glycemic control. BMC Endocr Disord 2010,10(1),5","journal-title":"BMC Endocr Disord"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.bbrc.2015.02.050","volume":"458","author":"Yuan Q.","year":"2015","unstructured":"Yuan Q.; Hu C.P.; Gong Z.C.; Bai Y.P.; Liu S.Y.; Li Y.J.; Jiang J.L.; Accelerated onset of senescence of endothelial progenitor cells in patients with type 2 diabetes mellitus: Role of dimethylarginine dimethylaminohydrolase 2 and asymmetric dimethylarginine. Biochem Biophys Res Commun 2015,458(4),869-876","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1007\/s00125-010-1843-4","volume":"53","author":"Reinhard H.","year":"2010","unstructured":"Reinhard H.; Jacobsen P.K.; Lajer M.; Pedersen N.; Billestrup N.; Mandrup-Poulsen T.; Parving H.H.; Rossing P.; Multifactorial treatment increases endothelial progenitor cells in patients with type 2 diabetes. Diabetologia 2010,53(10),2129-2133","journal-title":"Diabetologia"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1161\/01.ATV.0000156401.04325.8f","volume":"25","author":"Kr\u00e4nkel N.","year":"2005","unstructured":"Kr\u00e4nkel N.; Adams V.; Linke A.; Gielen S.; Erbs S.; Lenk K.; Schuler G.; Hambrecht R.; Hyperglycemia reduces survival and impairs function of circulating blood-derived progenitor cells. Arterioscler Thromb Vasc Biol 2005,25(4),698-703","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1161\/01.CIR.0000039526.42991.93","volume":"106","author":"Tepper O.M.","year":"2002","unstructured":"Tepper O.M.; Galiano R.D.; Capla J.M.; Kalka C.; Gagne P.J.; Jacobowitz G.R.; Levine J.P.; Gurtner G.C.; Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 2002,106(22),2781-2786","journal-title":"Circulation"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.2337\/db06-1103","volume":"56","author":"Chen Y.H.","year":"2007","unstructured":"Chen Y.H.; Lin S.J.; Lin F.Y.; Wu T.C.; Tsao C.R.; Huang P.H.; Liu P.L.; Chen Y.L.; Chen J.W.; High glucose impairs early and late endothelial progenitor cells by modifying nitric oxide-related but not oxidative stress-mediated mechanisms. Diabetes 2007,56(6),1559-1568","journal-title":"Diabetes"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1177\/1479164112444639","volume":"10","author":"Zhang J.","year":"2013","unstructured":"Zhang J.; Zhang X.; Li H.; Cui X.; Guan X.; Tang K.; Jin C.; Cheng M.; Hyperglycaemia exerts deleterious effects on late endothelial progenitor cell secretion actions. Diab Vasc Dis Res 2013,10(1),49-56","journal-title":"Diab Vasc Dis Res"},{"key":"ref=78","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/stem.1280","volume":"31","author":"Tura O.","year":"2013","unstructured":"Tura O.; Skinner E.M.; Barclay G.R.; Samuel, K.; Gallagher R.C.; Brittan M.; Hadoke P.W.; Newby D.E.; Turner M.L.; Mills N.L.; Late outgrowth endothelial cells resemble mature endothelial cells and are not derived from bone marrow. Stem Cells 2013,31(2),338-348","journal-title":"Stem Cells"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s12933-016-0413-6","volume":"15","author":"Ahmed F.W.","year":"2016","unstructured":"Ahmed F.W.; Rider R.; Glanville M.; Narayanan K.; Razvi S.; Weaver J.U.; Metformin improves circulating endothelial cells and endothelial progenitor cells in type 1 diabetes: MERIT study. Cardiovasc Diabetol 2016,15(1),116","journal-title":"Cardiovasc Diabetol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1007\/s12020-010-9383-8","volume":"38","author":"Chen L.L.","year":"2010","unstructured":"Chen L.L.; Liao Y.F.; Zeng T.S.; Yu F.; Li H.Q.; Feng Y.; Effects of metformin plus gliclazide compared with metformin alone on circulating endothelial progenitor cell in type 2 diabetic patients. Endocrine 2010,38(2),266-275","journal-title":"Endocrine"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12933-018-0709-9","volume":"17","author":"Dore F.J.","year":"2018","unstructured":"Dore F.J.; Domingues C.C.; Ahmadi N.; Kundu N.; Kropotova Y.; Houston S.; Rouphael C.; Mammadova A.; Witkin L.; Khiyami A.; Amdur R.L.; Sen S.; The synergistic effects of saxagliptin and metformin on CD34+ endothelial progenitor cells in early type 2 diabetes patients: A randomized clinical trial. Cardiovasc Diabetol 2018,17(1),65-65","journal-title":"Cardiovasc Diabetol"},{"key":"ref=82","first-page":"1475","volume":"15","author":"Yu J.W.","year":"2016","unstructured":"Yu J.W.; Deng Y.P.; Han X.; Ren G.F.; Cai J.; Jiang G.J.; Metformin improves the angiogenic functions of endothelial progenitor cells via activating AMPK\/eNOS pathway in diabetic mice. Cardiovasc Diabetol 2016,15,1475-2840","journal-title":"Cardiovasc Diabetol"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"8691","DOI":"10.3892\/mmr.2017.7707","volume":"16","author":"Han X.","year":"2017","unstructured":"Han X.; Tao Y.; Deng Y.; Yu J.; Sun Y.; Jiang G.; Metformin accelerates wound healing in type 2 diabetic db\/db mice. Mol Med Rep 2017,16(6),8691-8698","journal-title":"Mol Med Rep"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1093\/carcin\/bgu001","volume":"35","author":"Dallaglio K.","year":"2014","unstructured":"Dallaglio K.; Bruno A.; Cantelmo A.R.; Esposito A.I.; Ruggiero L.; Orecchioni S.; Calleri A.; Bertolini F.; Pfeffer U.; Noonan D.M.; Albini A.; Paradoxic effects of metformin on endothelial cells and angiogenesis. Carcinogenesis 2014,35(5),1055-1066","journal-title":"Carcinogenesis"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.bbrc.2015.08.091","volume":"465","author":"Li W.D.","year":"2015","unstructured":"Li W.D.; Du X.L.; Qian A.M.; Hu N.; Kong L.S.; Wei S.; Li C.L.; Li X.Q.; Metformin regulates differentiation of bone marrow-derived endothelial progenitor cells via multiple mechanisms. Biochem Biophys Res Commun 2015,465(4),803-809","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.3892\/ijmm.2017.2929","volume":"39","author":"Li W.D.","year":"2017","unstructured":"Li W.D.; Li N.P.; Song D.D.; Rong J.J.; Qian A.M.; Li X.Q.; Metformin inhibits endothelial progenitor cell migration by decreasing matrix metalloproteinases, MMP-2 and MMP-9, via the AMPK\/mTOR\/autophagy pathway. Int J Mol Med 2017,39(5),1262-1268","journal-title":"Int J Mol Med"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2165\/11534750-000000000-00000","volume":"50","author":"Graham G.G.","year":"2011","unstructured":"Graham G.G.; Punt J.; Arora M.; Day R.O.; Doogue M.P.; Duong J.K.; Furlong T.J.; Greenfield J.R.; Greenup L.C.; Kirkpatrick C.M.; Ray J.E.; Timmins P.; Williams K.M.; Clinical pharmacokinetics of metformin. Clin Pharmacokinet 2011,50(2),81-98","journal-title":"Clin Pharmacokinet"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.cell.2013.02.035","volume":"153","author":"Cabreiro F.","year":"2013","unstructured":"Cabreiro F.; Au C.; Leung K.Y.; Vergara-Irigaray N.; Cochem\u00e9 H.M.; Noori T.; Weinkove D.; Schuster E.; Greene N.D.; Gems D.; Metformin retards aging in C. elegans by altering microbial folate and methionine metabolism. Cell 2013,153(1),228-239","journal-title":"Cell"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"6","DOI":"10.7554\/eLife.31268","volume":"6","author":"Chen J.","year":"2017","unstructured":"Chen J.; Ou Y.; Li Y.; Hu S.; Shao L.W.; Liu Y.; Metformin extends C. elegans lifespan through lysosomal pathway. eLife 2017,6,6","journal-title":"eLife"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1038\/s42255-020-00307-1","volume":"2","author":"Espada L.","year":"2020","unstructured":"Espada L.; Dakhovnik A.; Chaudhari P.; Martirosyan A.; Miek L.; Poliezhaieva T.; Schaub Y.; Nair A.; D\u00f6ring N.; Rahnis N.; Werz O.; Koeberle A.; Kirkpatrick J.; Ori A.; Ermolaeva M.A.; Loss of metabolic plasticity underlies metformin toxicity in aged Caenorhabditis elegans. Nat Metab 2020,2(11),1316-1331","journal-title":"Nat Metab"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"148","DOI":"10.18632\/aging.100273","volume":"3","author":"Anisimov V.N.","year":"2011","unstructured":"Anisimov V.N.; Berstein L.M.; Popovich I.G.; Zabezhinski M.A.; Egormin P.A.; Piskunova T.S.; Semenchenko A.V.; Tyndyk M.L.; Yurova M.N.; Kovalenko I.G.; Poroshina T.E.; If started early in life, metformin treatment increases life span and postpones tumors in female SHR mice. Aging (Albany NY) 2011,3(2),148-157","journal-title":"Aging (Albany NY)"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1093\/gerona\/glq033","volume":"65","author":"Smith D.L.","year":"2010","unstructured":"Smith D.L.; Elam C.F.; Mattison J.A.; Lane M.A.; Roth G.S.; Ingram D.K.; Allison D.B.; Metformin supplementation and life span in Fischer-344 rats. J Gerontol A Biol Sci Med Sci 2010,65(5),468-474","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1111\/acel.12496","volume":"15","author":"Strong R.","year":"2016","unstructured":"Strong R.; Miller R.A.; Antebi A.; Astle C.M.; Bogue M.; Denzel M.S.; Fernandez E.; Flurkey K.; Hamilton K.L.; Lamming D.W.; Javors M.A.; de Magalh\u00e3es J.P.; Martinez P.A.; McCord J.M.; Miller B.F.; M\u00fcller M.; Nelson J.F.; Ndukum J.; Rainger G.E.; Richardson A.; Sabatini D.M.; Salmon A.B.; Simpkins J.W.; Steegenga W.T.; Nadon N.L.; Harrison D.E.; Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an \u03b1-glucosidase inhibitor or a Nrf2-inducer. Aging Cell 2016,15(5),872-884","journal-title":"Aging Cell"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1159\/000502257","volume":"65","author":"Glossmann H.H.","year":"2019","unstructured":"Glossmann H.H.; Lutz O.M.D.; Metformin and aging: A review. Gerontology 2019,65(6),581-590","journal-title":"Gerontology"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/sms.12581","volume":"25","author":"Pedersen B.K.","year":"2015","unstructured":"Pedersen B.K.; Saltin B.; Exercise as medicine - evidence for prescribing exercise as therapy in 26 different chronic diseases. Scand J Med Sci Sports 2015,25(Suppl. 3),1-72","journal-title":"Scand J Med Sci Sports"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.2165\/00007256-200838120-00005","volume":"38","author":"Leung F.P.","year":"2008","unstructured":"Leung F.P.; Yung L.M.; Laher I.; Yao X.; Chen Z.Y.; Huang Y.; Exercise, vascular wall and cardiovascular diseases: An update (Part 1). Sports Med 2008,38(12),1009-1024","journal-title":"Sports Med"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.cell.2008.06.051","volume":"134","author":"Narkar V.A.","year":"2008","unstructured":"Narkar V.A.; Downes M.; Yu R.T.; Embler E.; Wang Y.X.; Banayo E.; Mihaylova M.M.; Nelson M.C.; Zou Y.; Juguilon H.; Kang H.; Shaw R.J.; Evans R.M.; AMPK and PPARdelta agonists are exercise mimetics. Cell 2008,134(3),405-415","journal-title":"Cell"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1249\/JES.0000000000000070","volume":"44","author":"Malin S.K.","year":"2016","unstructured":"Malin S.K.; Braun B.; Impact of metformin on exercise-induced metabolic adaptations to lower type 2 diabetes risk. Exerc Sport Sci Rev 2016,44(1),4-11","journal-title":"Exerc Sport Sci Rev"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"e12880","DOI":"10.1111\/acel.12880","volume":"18","author":"Konopka A.R.","year":"2019","unstructured":"Konopka A.R.; Laurin J.L.; Schoenberg H.M.; Reid J.J.; Castor W.M.; Wolff C.A.; Musci R.V.; Safairad O.D.; Linden M.A.; Biela L.M.; Bailey S.M.; Hamilton K.L.; Miller B.F.; Metformin inhibits mitochondrial adaptations to aerobic exercise training in older adults. Aging Cell 2019,18(1),e12880","journal-title":"Aging Cell"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.metabol.2019.01.004","volume":"94","author":"Terada T.","year":"2019","unstructured":"Terada T.; Boul\u00e9 N.G.; Does metformin therapy influence the effects of intensive lifestyle intervention? Exploring the interaction between first line therapies in the Look AHEAD trial. Metabolism 2019,94,39-46","journal-title":"Metabolism"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"e13039","DOI":"10.1111\/acel.13039","volume":"18","author":"Walton R.G.","year":"2019","unstructured":"Walton R.G.; Dungan C.M.; Long D.E.; Tuggle S.C.; Kosmac K.; Peck B.D.; Bush H.M.; Villasante Tezanos A.G.; McGwin G.; Windham S.T.; Ovalle F.; Bamman M.M.; Kern P.A.; Peterson C.A.; Metformin blunts muscle hypertrophy in response to progressive resistance exercise training in older adults: A randomized, double-blind, placebo-controlled, multicenter trial: The MASTERS trial. Aging Cell 2019,18(6),e13039","journal-title":"Aging Cell"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"131","DOI":"10.2337\/dc11-0925","volume":"35","author":"Malin S.K.","year":"2012","unstructured":"Malin S.K.; Gerber R.; Chipkin S.R.; Braun B.; Independent and combined effects of exercise training and metformin on insulin sensitivity in individuals with prediabetes. Diabetes Care 2012,35(1),131-136","journal-title":"Diabetes Care"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41598-020-80603-8","volume":"11","author":"Gebrie D.","year":"2021","unstructured":"Gebrie D.; Getnet D.; Manyazewal T.; Cardiovascular safety and efficacy of metformin-SGLT2i versus metformin-sulfonylureas in type 2 diabetes: Systematic review and meta-analysis of randomized controlled trials. Sci Rep 2021,11(1),137","journal-title":"Sci Rep"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.2337\/dc20-2080","volume":"44","author":"Zaccardi F.","year":"2021","unstructured":"Zaccardi F.; Kloecker D.E.; Buse J.B.; Mathieu C.; Khunti K.; Davies M.J.; Use of metformin and cardiovascular effects of new classes of glucose-lowering agents: A meta-analysis of cardiovascular outcome trials in type 2 diabetes. Diabetes Care 2021,44(2),e32-e34","journal-title":"Diabetes Care"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1093\/eurjpc\/zwaa074","volume":"28","author":"Masson W.","year":"2021","unstructured":"Masson W.; Lavalle-Cobo A.; Lobo M.; Masson G.; Molinero G.; Novel antidiabetic drugs and risk of cardiovascular events in patients without baseline metformin use: A meta-analysis. Eur J Prev Cardiol 2021,28(1),69-75","journal-title":"Eur J Prev Cardiol"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12933-018-0797-6","volume":"17","author":"Lunder M.","year":"2018","unstructured":"Lunder M.; Jani\u0107 M.; Japelj M.; Jureti\u010d A.; Jane\u017e A.; \u0160abovi\u010d M.; Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus. Cardiovasc Diabetol 2018,17(1),153","journal-title":"Cardiovasc Diabetol"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1080\/17512433.2019.1588110","volume":"12","author":"Singh A.K.","year":"2019","unstructured":"Singh A.K.; Singh R.; Heart failure hospitalization with SGLT-2 inhibitors: A systematic review and meta-analysis of randomized controlled and observational studies. Expert Rev Clin Pharmacol 2019,12(4),299-308","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.3390\/biom11121834","volume":"11","author":"Salvatore T.","year":"2021","unstructured":"Salvatore T.; Galiero R.; Caturano A.; Vetrano E.; Rinaldi L.; Coviello F.; Di Martino A.; Albanese G.; Marfella R.; Sardu C.; Sasso F.C.; Effects of metformin in heart failure: From pathophysiological rationale to clinical evidence. Biomolecules 2021,11(12),1834","journal-title":"Biomolecules"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S2213-8587(21)00059-0","volume":"9","author":"Schernthaner G.","year":"2021","unstructured":"Schernthaner G.; Can glucose-lowering drugs affect the prognosis of COVID-19 in patients with type 2 diabetes? Lancet Diabetes Endocrinol 2021,9(5),251-252","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ahj.2020.09.020","volume":"231","author":"Wiggers H.","year":"2021","unstructured":"Wiggers H.; K\u00f8ber L.; Gislason G.; Schou M.; Poulsen M.K.; Vraa S.; Nielsen O.W.; Bruun N.E.; N\u00f8rrelund H.; Hollingdal M.; Barasa A.; B\u00f8ttcher M.; Dodt K.; Hansen V.B.; Nielsen G.; Knudsen A.S.; Lomholdt J.; Mikkelsen K.V.; Jonczy B.; Br\u00f8nnum-Schou J.; Poenaru M.P.; Abdulla J.; Raymond I.; Mahboubi K.; Sillesen K.; Serup-Hansen K.; Madsen J.S.; Kristensen S.L.; Larsen A.H.; B\u00f8tker H.E.; Torp-Petersen C.; Eiskj\u00e6r H.; M\u00f8ller J.; Hassager C.; Steffensen F.H.; Bibby B.M.; Refsgaard J.; H\u00f8fsten D.E.; Mellemkj\u00e6r S.; Gustafsson F.; The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 \u00d7 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chronic heart failure and diabetes or prediabetes (Met-HeFT). Am Heart J 2021,231,137-146","journal-title":"Am Heart J"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.clinthera.2020.12.015","volume":"43","author":"Farmer R.E.","year":"2021","unstructured":"Farmer R.E.; Beard I.; Raza S.I.; Gollop N.D.; Patel N.; Tebboth A.; McGovern A.P.; Kanumilli N.; Ternouth A.; Prescribing in type 2 diabetes patients with and without cardiovascular disease history: A descriptive analysis in the UK CPRD. Clin Ther 2021,43(2),320-335","journal-title":"Clin Ther"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"E162","DOI":"10.9778\/cmajo.20130073","volume":"2","author":"Hemmingsen B.","year":"2014","unstructured":"Hemmingsen B.; Schroll J.B.; Wetterslev J.; Gluud C.; Vaag A.; Sonne D.P.; Lundstr\u00f8m L.H.; Almdal T.; Sulfonylurea versus metformin monotherapy in patients with type 2 diabetes: A Cochrane systematic review and meta-analysis of randomized clinical trials and trial sequential analysis. CMAJ Open 2014,2(3),E162-E175","journal-title":"CMAJ Open"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1001\/jama.281.21.2005","volume":"281","author":"Turner R.C.","year":"1999","unstructured":"Turner R.C.; Cull C.A.; Frighi V.; Holman R.R.; Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). JAMA 1999,281(21),2005-2012","journal-title":"JAMA"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.kint.2020.04.059","volume":"98","author":"De Broe M.E.","year":"2020","unstructured":"De Broe M.E.; Jouret F.; Does metformin do more benefit or harm in chronic kidney disease patients? Kidney Int 2020,98(5),1098-1101","journal-title":"Kidney Int"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.kint.2020.04.060","volume":"98","author":"Hanna R.M.","year":"2020","unstructured":"Hanna R.M.; Rhee C.M.; Kalantar-Zadeh K.; Metformin in chronic kidney disease: A strong dose of caution. Kidney Int 2020,98(5),1101-1105","journal-title":"Kidney Int"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/ijms20010042","volume":"20","author":"Corremans R.","year":"2018","unstructured":"Corremans R.; Vervaet B.A.; D\u2019Haese P.C.; Neven E.; Verhulst A.; Metformin: A candidate drug for renal diseases. Int J Mol Sci 2018,20(1),42","journal-title":"Int J Mol Sci"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"547","DOI":"10.2337\/dc17-2231","volume":"41","author":"Lalau J-D.","year":"2018","unstructured":"Lalau J-D.; Kajbaf F.; Bennis Y.; Hurtel-Lemaire A-S.; Belpaire F.; De Broe M.E.; Metformin treatment in patients with type 2 diabetes and chronic kidney disease stages 3A, 3B, or 4. Diabetes Care 2018,41(3),547-553","journal-title":"Diabetes Care"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"107879","DOI":"10.1016\/j.diabres.2019.107879","volume":"157","author":"Salvatore T.","year":"2019","unstructured":"Salvatore T.; Pafundi P.C.; Marfella R.; Sardu C.; Rinaldi L.; Monaco L.; Ricozzi C.; Imbriani S.; Nevola R.; Adinolfi L.E.; Sasso F.C.; Metformin lactic acidosis: Should we still be afraid? Diabetes Res Clin Pract 2019,157,107879","journal-title":"Diabetes Res Clin Pract"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/pds.3432","volume":"22","author":"Hung A.M.","year":"2013","unstructured":"Hung A.M.; Roumie C.L.; Greevy R.A.; Liu X.; Grijalva C.G.; Murff H.J.; Griffin M.R.; Kidney function decline in metformin versus sulfonylurea initiators: Assessment of time-dependent contribution of weight, blood pressure, and glycemic control. Pharmacoepidemiol Drug Saf 2013,22(6),623-631","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"191","DOI":"10.7326\/M16-1901","volume":"166","author":"Crowley M.J.","year":"2017","unstructured":"Crowley M.J.; Diamantidis C.J.; McDuffie J.R.; Cameron C.B.; Stanifer J.W.; Mock C.K.; Wang X.; Tang S.; Nagi A.; Kosinski A.S.; Williams J.W.; Clinical outcomes of metformin use in populations with chronic kidney disease, congestive heart failure, or chronic liver disease: A systematic review. Ann Intern Med 2017,166(3),191-200","journal-title":"Ann Intern Med"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1159\/000370034","volume":"40","author":"Stephen J.","year":"2014","unstructured":"Stephen J.; Anderson-Haag T.L.; Gustafson S.; Snyder J.J.; Kasiske B.L.; Israni A.K.; Metformin use in kidney transplant recipients in the United States: An observational study. Am J Nephrol 2014,40(6),546-553","journal-title":"Am J Nephrol"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"e285","DOI":"10.1097\/TP.0000000000002864","volume":"103","author":"Lin C-X.","year":"2019","unstructured":"Lin C-X.; Li Y.; Liang S.; Tao J.; Zhang L-S.; Su Y-F.; Huang Y-X.; Zhao Z-K.; Liu S-Y.; Zheng J-M.; Metformin attenuates cyclosporine A-induced renal fibrosis in rats. Transplantation 2019,103(10),e285-e296","journal-title":"Transplantation"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.kint.2018.01.027","volume":"94","author":"Neven E.","year":"2018","unstructured":"Neven E.; Vervaet B.; Brand K.; Gottwald-Hostalek U.; Opdebeeck B.; De Mar\u00e9 A.; Verhulst A.; Lalau J-D.; Kamel S.; De Broe M.E.; D\u2019Haese P.C.; Metformin prevents the development of severe chronic kidney disease and its associated mineral and bone disorder. Kidney Int 2018,94(1),102-113","journal-title":"Kidney Int"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"F727","DOI":"10.1152\/ajprenal.00293.2013","volume":"305","author":"Satriano J.","year":"2013","unstructured":"Satriano J.; Sharma K.; Blantz R.C.; Deng A.; Induction of AMPK activity corrects early pathophysiological alterations in the subtotal nephrectomy model of chronic kidney disease. Am J Physiol Renal Physiol 2013,305(5),F727-F733","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"172959","DOI":"10.1016\/j.ejphar.2020.172959","volume":"872","author":"Mohamad H.E.","year":"2020","unstructured":"Mohamad H.E.; Asker M.E.; Keshawy M.M.; Abdel Aal S.M.; Mahmoud Y.K.; Infliximab ameliorates tumor necrosis factor-alpha exacerbated renal insulin resistance induced in rats by regulating insulin signaling pathway. Eur J Pharmacol 2020,872,172959","journal-title":"Eur J Pharmacol"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"8742","DOI":"10.18632\/aging.103095","volume":"12","author":"Pan Q.","year":"2020","unstructured":"Pan Q.; Lu X.; Zhao C.; Liao S.; Chen X.; Guo F.; Yang C.; Liu H.F.; Metformin: The updated protective property in kidney disease. Aging (Albany NY) 2020,12(9),8742-8759","journal-title":"Aging (Albany NY)"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"111454","DOI":"10.1016\/j.biopha.2021.111454","volume":"138","author":"Song A.","year":"2021","unstructured":"Song A.; Zhang C.; Meng X.; Mechanism and application of metformin in kidney diseases: An update. Biomed Pharmacother 2021,138,111454","journal-title":"Biomed Pharmacother"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.2337\/dc20-0660","volume":"43","author":"Chen Y.","year":"2020","unstructured":"Chen Y.; Yang D.; Cheng B.; Chen J.; Peng A.; Yang C.; Liu C.; Xiong M.; Deng A.; Zhang Y.; Zheng L.; Huang K.; Clinical characteristics and outcomes of patients with diabetes and COVID-19 in association with glucose-lowering medication. Diabetes Care 2020,43(7),1399-1407","journal-title":"Diabetes Care"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s40618-020-01236-2","volume":"43","author":"Fadini G.P.","year":"2020","unstructured":"Fadini G.P.; Morieri M.L.; Longato E.; Avogaro A.; Prevalence and impact of diabetes among people infected with SARS-CoV-2. J Endocrinol Invest 2020,43(6),867-869","journal-title":"J Endocrinol Invest"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","volume":"382","author":"Guan W.J.","year":"2020","unstructured":"Guan W.J.; Ni Z.Y.; Hu Y.; Liang W.H.; Ou C.Q.; He J.X.; Liu L.; Shan H.; Lei C.L.; Hui D.S.C.; Du B.; Li L.J.; Zeng G.; Yuen K-Y.; Chen R.C.; Tang C.L.; Wang T.; Chen P.Y.; Xiang J.; Li S.Y.; Wang J.L.; Liang Z.J.; Peng Y.X.; Wei L.; Liu Y.; Hu Y.H.; Peng P.; Wang J.M.; Liu J.Y.; Chen Z.; Li G.; Zheng Z.J.; Qiu S.Q.; Luo J.; Ye C.J.; Zhu S.Y.; Zhong N.S.; 2019 in China. N Engl J Med 2020,382(18),1708-1720","journal-title":"N Engl J Med"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1001\/jamainternmed.2020.0994","volume":"180","author":"Wu C.","year":"2020","unstructured":"Wu C.; Chen X.; Cai Y.; Xia J.; Zhou X.; Xu S.; Huang H.; Zhang L.; Zhou X.; Du C.; Zhang Y.; Song J.; Wang S.; Chao Y.; Yang Z.; Xu J.; Zhou X.; Chen D.; Xiong W.; Xu L.; Zhou F.; Jiang J.; Bai C.; Zheng J.; Song Y.; 2019 Pneumonia in Wuhan, China. JAMA Intern Med 2020,180(7),934-943","journal-title":"JAMA Intern Med"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"21011","DOI":"10.1073\/pnas.2011086117","volume":"117","author":"Hamer M.","year":"2020","unstructured":"Hamer M.; Gale C.R.; Kivim\u00e4ki M.; Batty G.D.; Overweight, obesity, and risk of hospitalization for COVID-19: A community-based cohort study of adults in the United Kingdom. Proc Natl Acad Sci USA 2020,117(35),21011-21013","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.cmet.2021.01.016","volume":"33","author":"Drucker D.J.","year":"2021","unstructured":"Drucker D.J.; Diabetes, obesity, metabolism, and SARS-CoV-2 infection: The end of the beginning. Cell Metab 2021,33(3),479-498","journal-title":"Cell Metab"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.2337\/dc20-1380","volume":"43","author":"Coppelli A.","year":"2020","unstructured":"Coppelli A.; Giannarelli R.; Aragona M.; Penno G.; Falcone M.; Tiseo G.; Ghiadoni L.; Barbieri G.; Monzani F.; Virdis A.; Menichetti F.; Del Prato S.; Hyperglycemia at hospital admission is associated with severity of the prognosis in patients hospitalized for COVID-19: The pisa COVID-19 study. Diabetes Care 2020,43(10),2345-2348","journal-title":"Diabetes Care"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.jcrc.2019.11.003","volume":"55","author":"Mamtani M.","year":"2020","unstructured":"Mamtani M.; Kulkarni H.; Bihari S.; Prakash S.; Chavan S.; Huckson S.; Pilcher D.; Degree of hyperglycemia independently associates with hospital mortality and length of stay in critically ill, nondiabetic patients: Results from the ANZICS CORE binational registry. J Crit Care 2020,55,149-156","journal-title":"J Crit Care"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.cmet.2020.04.021","volume":"31","author":"Zhu L.","year":"2020","unstructured":"Zhu L.; She Z.G.; Cheng X.; Qin J.J.; Zhang X.J.; Cai J.; Lei F.; Wang H.; Xie J.; Wang W.; Li H.; Zhang P.; Song X.; Chen X.; Xiang M.; Zhang C.; Bai L.; Xiang D.; Chen M.M.; Liu Y.; Yan Y.; Liu M.; Mao W.; Zou J.; Liu L.; Chen G.; Luo P.; Xiao B.; Zhang C.; Zhang Z.; Lu Z.; Wang J.; Lu H.; Xia X.; Wang D.; Liao X.; Peng G.; Ye P.; Yang J.; Yuan Y.; Huang X.; Guo J.; Zhang B.H.; Li H.; Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes. Cell Metab 2020,31(6),1068-1077.e3","journal-title":"Cell Metab"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"108186","DOI":"10.1016\/j.diabres.2020.108186","volume":"163","author":"Ceriello A.","year":"2020","unstructured":"Ceriello A.; Hyperglycemia and the worse prognosis of COVID-19. Why a fast blood glucose control should be mandatory. Diabetes Res Clin Pract 2020,163,108186","journal-title":"Diabetes Res Clin Pract"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1016\/j.cmet.2021.09.009","volume":"33","author":"Reiterer M.","year":"2021","unstructured":"Reiterer M.; Rajan M.; G\u00f3mez-Banoy N.; Lau J.D.; Gomez-Escobar L.G.; Ma L.; Gilani A.; Alvarez-Mulett S.; Sholle E.T.; Chandar V.; Bram Y.; Hoffman K.; Bhardwaj P.; Piloco P.; Rubio-Navarro A.; Uhl S.; Carrau L.; Houhgton S.; Redmond D.; Shukla A.P.; Goyal P.; Brown K.A.; tenOever B.R.; Alonso L.C.; Schwartz R.E.; Schenck E.J.; Safford M.M.; Lo J.C.; Hyperglycemia in acute COVID-19 is characterized by insulin resistance and adipose tissue infectivity by SARS-CoV-2. Cell Metab 2021,33(11),2174-2188.e5","journal-title":"Cell Metab"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"154894","DOI":"10.1016\/j.metabol.2021.154894","volume":"128","author":"Kim N.H.","year":"2022","unstructured":"Kim N.H.; Kim K.J.; Choi J.; Kim S.G.; Metabolically unhealthy individuals, either with obesity or not, have a higher risk of critical coronavirus disease 2019 outcomes than metabolically healthy individuals without obesity. Metabolism 2022,128,154894","journal-title":"Metabolism"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"155121","DOI":"10.1016\/j.metabol.2021.155121","volume":"128","author":"Sanoudou D.","year":"2022","unstructured":"Sanoudou D.; Hill M.A.; Belanger M.J.; Arao K.; Mantzoros C.S.; Editorial: Obesity, metabolic phenotypes and COVID-19. Metabolism 2022,128,155121","journal-title":"Metabolism"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.1016\/S2666-7568(20)30033-7","volume":"2","author":"Bramante C.T.","year":"2021","unstructured":"Bramante C.T.; Ingraham N.E.; Murray T.A.; Marmor S.; Hovertsen S.; Gronski J.; McNeil C.; Feng R.; Guzman G.; Abdelwahab N.; King S.; Tamariz L.; Meehan T.; Pendleton K.M.; Benson B.; Vojta D.; Tignanelli C.J.; Metformin and risk of mortality in patients hospitalised with COVID-19: A retrospective cohort analysis. Lancet Healthy Longev 2021,2(1),e34-e41","journal-title":"Lancet Healthy Longev"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1016\/j.dsx.2020.11.006","volume":"14","author":"Lukito A.A.","year":"2020","unstructured":"Lukito A.A.; Pranata R.; Henrina J.; Lim M.A.; Lawrensia S.; Suastika K.; The Effect of Metformin Consumption on Mortality in Hospitalized COVID-19 patients: A systematic review and meta-analysis. Diabetes Metab Syndr 2020,14(6),2177-2183","journal-title":"Diabetes Metab Syndr"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"4020","DOI":"10.1101\/2020.07.29.20164020","volume":"2020","author":"Crouse A.","year":"2020","unstructured":"Crouse A.; Grimes T.; Li P.; Might M.; Ovalle F.; Shalev A.; Metformin use is associated with reduced mortality in a diverse population with COVID-19 and diabetes. medRxiv 2020,2020,4020","journal-title":"medRxiv"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1007\/s00125-020-05351-w","volume":"64","author":"Wargny M.","year":"2021","unstructured":"Wargny M.; Potier L.; Gourdy P.; Pichelin M.; Amadou C.; Benhamou P.Y.; Bonnet J.B.; Bordier L.; Bourron O.; Chaumeil C.; Chevalier N.; Darmon P.; Delenne B.; Demarsy D.; Dumas M.; Dupuy O.; Flaus-Furmaniuk A.; Gautier J.F.; Guedj A.M.; Jeandidier N.; Larger E.; Le Berre J.P.; Lungo M.; Montanier N.; Moulin P.; Plat F.; Rigalleau V.; Robert R.; Seret-B\u00e9gu\u00e9 D.; S\u00e9rusclat P.; Smati S.; Th\u00e9baut J.F.; Tramunt B.; Vatier C.; Velayoudom F.L.; Verg\u00e8s B.; Winiszewski P.; Zabulon A.; Gourraud P.A.; Roussel R.; Cariou B.; Hadjadj S.; Predictors of hospital discharge and mortality in patients with diabetes and COVID-19: Updated results from the nationwide CORONADO study. Diabetologia 2021,64(4),778-794","journal-title":"Diabetologia"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"645194","DOI":"10.3389\/fendo.2021.645194","volume":"12","author":"Zangiabadian M.","year":"2021","unstructured":"Zangiabadian M.; Nejadghaderi S.A.; Zahmatkesh M.M.; Hajikhani B.; Mirsaeidi M.; Nasiri M.J.; The efficacy and potential mechanisms of metformin in the treatment of COVID-19 in the diabetics: A systematic review. Front Endocrinol (Lausanne) 2021,12,645194","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1515\/jpem-2011-0469","volume":"25","author":"Evia-Viscarra M.L.","year":"2012","unstructured":"Evia-Viscarra M.L.; Rodea-Montero E.R.; Apolinar-Jim\u00e9nez E.; Mu\u00f1oz-Noriega N.; Garc\u00eda-Morales L.M.; Lea\u00f1os-P\u00e9rez C.; Figueroa-Barr\u00f3n M.; S\u00e1nchez-Fierros D.; Reyes-Garc\u00eda J.G.; The effects of metformin on inflammatory mediators in obese adolescents with insulin resistance: Controlled randomized clinical trial. J Pediatr Endocrinol Metab 2012,25(1-2),41-49","journal-title":"J Pediatr Endocrinol Metab"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1161\/CIRCRESAHA.116.308445","volume":"119","author":"Cameron A.R.","year":"2016","unstructured":"Cameron A.R.; Morrison V.L.; Levin D.; Mohan M.; Forteath C.; Beall C.; McNeilly A.D.; Balfour D.J.; Savinko T.; Wong A.K.; Viollet B.; Sakamoto K.; Fagerholm S.C.; Foretz M.; Lang C.C.; Rena G.; Anti-inflammatory effects of metformin irrespective of diabetes status. Circ Res 2016,119(5),652-665","journal-title":"Circ Res"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"474","DOI":"10.4149\/BLL_2021_078","volume":"122","author":"Zahorec R.","year":"2021","unstructured":"Zahorec R.; Neutrophil-to-lymphocyte ratio, past, present and future perspectives. Bratisl Lek Listy 2021,122(7),474-488","journal-title":"Bratisl Lek Listy"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/s41586-020-2286-9","volume":"583","author":"Gordon D.E.","year":"2020","unstructured":"Gordon D.E.; Jang G.M.; Bouhaddou M.; Xu J.; Obernier K.; White K.M.; O\u2019Meara M.J.; Rezelj V.V.; Guo J.Z.; Swaney D.L.; Tummino T.A.; H\u00fcttenhain R.; Kaake R.M.; Richards A.L.; Tutuncuoglu B.; Foussard H.; Batra J.; Haas K.; Modak M.; Kim M.; Haas P.; Polacco B.J.; Braberg H.; Fabius J.M.; Eckhardt M.; Soucheray M.; Bennett M.J.; Cakir M.; McGregor M.J.; Li Q.; Meyer B.; Roesch F.; Vallet T.; Mac Kain A.; Miorin L.; Moreno E.; Naing Z.Z.C.; Zhou Y.; Peng S.; Shi Y.; Zhang Z.; Shen W.; Kirby I.T.; Melnyk J.E.; Chorba J.S.; Lou K.; Dai S.A.; Barrio-Hernandez I.; Memon D.; Hernandez-Armenta C.; Lyu J.; Mathy C.J.P.; Perica T.; Pilla K.B.; Ganesan S.J.; Saltzberg D.J.; Rakesh R.; Liu X.; Rosenthal S.B.; Calviello L.; Venkataramanan S.; Liboy-Lugo J.; Lin Y.; Huang X-P.; Liu Y.; Wankowicz S.A.; Bohn M.; Safari M.; Ugur F.S.; Koh C.; Savar N.S.; Tran Q.D.; Shengjuler D.; Fletcher S.J.; O\u2019Neal M.C.; Cai Y.; Chang J.C.J.; Broadhurst D.J.; Klippsten S.; Sharp P.P.; Wenzell N.A.; Kuzuoglu-Ozturk D.; Wang H-Y.; Trenker R.; Young J.M.; Cavero D.A.; Hiatt J.; Roth T.L.; Rathore U.; Subramanian A.; Noack J.; Hubert M.; Stroud R.M.; Frankel A.D.; Rosenberg O.S.; Verba K.A.; Agard D.A.; Ott M.; Emerman M.; Jura N.; von Zastrow M.; Verdin E.; Ashworth A.; Schwartz O.; d\u2019Enfert C.; Mukherjee S.; Jacobson M.; Malik H.S.; Fujimori D.G.; Ideker T.; Craik C.S.; Floor S.N.; Fraser J.S.; Gross J.D.; Sali A.; Roth B.L.; Ruggero D.; Taunton J.; Kortemme T.; Beltrao P.; Vignuzzi M.; Garc\u00eda-Sastre A.; Shokat K.M.; Shoichet B.K.; Krogan N.J.; A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 2020,583(7816),459-468","journal-title":"Nature"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1128\/AAC.03659-14","volume":"59","author":"Kindrachuk J.","year":"2015","unstructured":"Kindrachuk J.; Ork B.; Hart B.J.; Mazur S.; Holbrook M.R.; Frieman M.B.; Traynor D.; Johnson R.F.; Dyall J.; Kuhn J.H.; Olinger G.G.; Hensley L.E.; Jahrling P.B.; Antiviral potential of ERK\/MAPK and PI3K\/AKT\/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis. Antimicrob Agents Chemother 2015,59(2),1088-1099","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1164\/rccm.201712-2570OC","volume":"198","author":"Zhang J.","year":"2018","unstructured":"Zhang J.; Dong J.; Martin M.; He M.; Gongol B.; Marin T.L.; Chen L.; Shi X.; Yin Y.; Shang F.; Wu Y.; Huang H.Y.; Zhang J.; Zhang Y.; Kang J.; Moya E.A.; Huang H.D.; Powell F.L.; Chen Z.; Thistlethwaite P.A.; Yuan Z.Y.; Shyy J.Y.; AMP-activated protein kinase phosphorylation of angiotensin-converting enzyme 2 in endothelium mitigates pulmonary hypertension. Am J Respir Crit Care Med 2018,198(4),509-520","journal-title":"Am J Respir Crit Care Med"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"112230","DOI":"10.1016\/j.biopha.2021.112230","volume":"144","author":"Kamyshnyi O.","year":"2021","unstructured":"Kamyshnyi O.; Matskevych V.; Lenchuk T.; Strilbytska O.; Storey K.; Lushchak O.; Metformin to decrease COVID-19 severity and mortality: Molecular mechanisms and therapeutic potential. Biomed Pharmacother 2021,144,112230","journal-title":"Biomed Pharmacother"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1161\/CIRCRESAHA.120.317447","volume":"127","author":"McFadyen J.D.","year":"2020","unstructured":"McFadyen J.D.; Stevens H.; Peter K.; The emerging threat of (micro)thrombosis in COVID-19 and its therapeutic implications. Circ Res 2020,127(4),571-587","journal-title":"Circ Res"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/S0140-6736(20)30937-5","volume":"395","author":"Varga Z.","year":"2020","unstructured":"Varga Z.; Flammer A.J.; Steiger P.; Haberecker M.; Andermatt R.; Zinkernagel A.S.; Mehra M.R.; Schuepbach R.A.; Ruschitzka F.; Moch H.; Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020,395(10234),1417-1418","journal-title":"Lancet"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"107723","DOI":"10.1016\/j.jdiacomp.2020.107723","volume":"34","author":"Katsiki N.","year":"2020","unstructured":"Katsiki N.; Ferrannini E.; Anti-inflammatory properties of antidiabetic drugs: A \u201cpromised land\u201d in the COVID-19 era? J Diabetes Complications 2020,34(12),107723","journal-title":"J Diabetes Complications"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"S244","DOI":"10.2337\/dcS15-3015","volume":"39","author":"Pollack R.M.","year":"2016","unstructured":"Pollack R.M.; Donath M.Y.; LeRoith D.; Leibowitz G.; Anti-inflammatory agents in the treatment of diabetes and its vascular complications. Diabetes Care 2016,39(Suppl. 2),S244-S252","journal-title":"Diabetes Care"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1186\/s12916-020-01832-2","volume":"18","author":"P\u00e9rez-Belmonte L.M.","year":"2020","unstructured":"P\u00e9rez-Belmonte L.M.; Torres-Pe\u00f1a J.D.; L\u00f3pez-Carmona M.D.; Ayala-Guti\u00e9rrez M.M.; Fuentes-Jim\u00e9nez F.; Huerta L.J.; Mu\u00f1oz J.A.; Rubio-Rivas M.; Madrazo M.; Garcia M.G.; Montes B.V.; Sola J.F.; Ena J.; Ferrer R.G.; P\u00e9rez C.M.; Ripper C.J.; Lecumberri J.J.N.; Acedo I.E.A.; Canteli S.P.; Cos\u00edo S.F.; Mart\u00ednez F.A.; Rodr\u00edguez B.C.; P\u00e9rez-Mart\u00ednez P.; Ramos-Rinc\u00f3n J.M.; G\u00f3mez-Huelgas R.; Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: A nationwide cohort study. BMC Med 2020,18(1),359","journal-title":"BMC Med"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1007\/s00125-020-05180-x","volume":"63","author":"Cariou B.","year":"2020","unstructured":"Cariou B.; Hadjadj S.; Wargny M.; Pichelin M.; Al-Salameh A.; Allix I.; Amadou C.; Arnault G.; Baudoux F.; Bauduceau B.; Borot S.; Bourgeon-Ghittori M.; Bourron O.; Boutoille D.; Cazenave-Roblot F.; Chaumeil C.; Cosson E.; Coudol S.; Darmon P.; Disse E.; Ducet-Boiffard A.; Gaborit B.; Joubert M.; Kerlan V.; Laviolle B.; Marchand L.; Meyer L.; Potier L.; Prevost G.; Riveline J-P.; Robert R.; Saulnier P-J.; Sultan A.; Th\u00e9baut J-F.; Thivolet C.; Tramunt B.; Vatier C.; Roussel R.; Gautier J-F.; Gourdy P.; Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: The CORONADO study. Diabetologia 2020,63(8),1500-1515","journal-title":"Diabetologia"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S2213-8587(21)00050-4","volume":"9","author":"Khunti K.","year":"2021","unstructured":"Khunti K.; Knighton P.; Zaccardi F.; Bakhai C.; Barron E.; Holman N.; Kar P.; Meace C.; Sattar N.; Sharp S.; Wareham N.J.; Weaver A.; Woch E.; Young B.; Valabhji J.; Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: A nationwide observational study in England. Lancet Diabetes Endocrinol 2021,9(5),293-303","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41574-021-00509-x","volume":"17","author":"Hadjadj S.","year":"2021","unstructured":"Hadjadj S.; Wargny M.; Glucose-lowering treatments and COVID-19 mortality in T2DM. Nat Rev Endocrinol 2021,17(7),387-388","journal-title":"Nat Rev Endocrinol"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13098-021-00639-2","volume":"13","author":"Santos A.","year":"2021","unstructured":"Santos A.; Magro D.O.; Evangelista-Poderoso R.; Saad M.J.A.; Diabetes, obesity, and insulin resistance in COVID-19: Molecular interrelationship and therapeutic implications. Diabetol Metab Syndr 2021,13(1),23","journal-title":"Diabetol Metab Syndr"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/bcpt.13273","volume":"125","author":"Stevens A.","year":"2019","unstructured":"Stevens A.; Hamel J.F.; Toure A.; Hadjadj S.; Boels D.; Metformin overdose: A serious iatrogenic complication\u2014Western france poison control centre data analysis. Basic Clin Pharmacol Toxicol 2019,125(5),466-473","journal-title":"Basic Clin Pharmacol Toxicol"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867329666220729154615","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/207135\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867329666220729154615","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T19:55:26Z","timestamp":1693684526000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/207135\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":162,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867329666220729154615","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-02-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-08","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}